Share

Two experimental Ebola vaccines appear safe

accreditation
Stop Ebola from Shutterstock
Stop Ebola from Shutterstock

Two experimental Ebola vaccines, tested in Liberia on more than 600 people in a phase 2 clinical trial appear to be safe, the US National Institute of Allergy and Infectious Diseases (NIAID) said on Thursday.

Killed more than 10,000 people

The results confirm two clinical trials, each with some 20 people, that were carried out earlier in the United States.

The current, unprecedented epidemic of the disease has killed more than 10,000 people since it first emerged in early 2014 in west Africa, mainly in Liberia, Sierra Leone and Guinea.

The two new vaccines are known as VSV-EBOV, developed by the British company GlaxoSmithKline and the NIAID, and VSV-ZEBOV, developed by the Public Health Agency of Canada and licensed to NewLink Genetics and Merck, both American firms.

Read: Ebola vaccine trials begin in Liberia

The test is continuing by raising the number of subjects to around 1,500 people, and also to include a higher proportion of women, which is currently about 16 percent, the US agency said in a statement. The test is aimed at determining how effective the vaccines are.

There will be a follow-up period of at least one year. Two more blood samples will be taken from all volunteers at six and 12 months post-vaccination to ascertain how durable the immune responses are.

Infections continue to emerge

Researchers had planned to enlist 27,000 people in Liberia at risk of Ebola, such as health care workers, for the phase 3 portion of the trial.

But in Liberia there has been only one new confirmed case of the disease since February 19 of this year. So the leaders of the trial have decided to explore the possibility of extending the testing to other sites in other West African countries where infections continue to emerge.

Read: Ebola update: vaccine testing underway

Another phase 3 trial began in early March in Guinea with the VSV-EBOV vaccine of NIAID and GlaxoSmithKline.

As it stands today, there is no treatment or vaccine authorised to fight the Ebola virus, and the World Health Organisation has given the green light to speed up clinical trials of promising vaccines against the disease.

Scientists say it is not known what level of immune response is needed to protect people against the virus.

Read more:

Drug and vaccine makers in race against Ebola

Intravenous fluid could save many Ebola patients

Inhaled Ebola vaccine protects monkeys

Image: Stop Ebola from Shutterstock

We live in a world where facts and fiction get blurred
Who we choose to trust can have a profound impact on our lives. Join thousands of devoted South Africans who look to News24 to bring them news they can trust every day. As we celebrate 25 years, become a News24 subscriber as we strive to keep you informed, inspired and empowered.
Join News24 today
heading
description
username
Show Comments ()
Editorial feedback and complaints

Contact the public editor with feedback for our journalists, complaints, queries or suggestions about articles on News24.

LEARN MORE